Primary hyperparathyroidism. An alternative to the surgery;Hiperparatiroidismo primario. Una alternativa a la cirugía

Endocrinologia y Nutricion

Volumn 56, Issue 3, 2009, Pages 132-135

  Díaz Guardiola, Patricia ^a   Vega Piñero, Belén ^a   Alameda Hernando, Carmen ^b   Pavón de Paz, Isabel ^a   Iglesias Bolaños, Paloma ^a   Guijarro de Armas, Guadalupe ^a  

^a HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

Author keywords

Calcimimetic; Cinacalcet; Hypercalcemia; Hyperparathyroidism; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CINACALCET; DIURETIC AGENT; PARATHYROID HORMONE; ZOLEDRONIC ACID;

ADENOMA; AGED; ARTICLE; CASE REPORT; FEMALE; HUMAN; HYPERCALCEMIA; PRIMARY HYPERPARATHYROIDISM; SURGICAL RISK; SURGICAL TECHNIQUE;

ADENOMA; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; CARCINOMA, RENAL CELL; COMORBIDITY; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; FEMALE; FLUID THERAPY; FUROSEMIDE; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM, PRIMARY; IMIDAZOLES; KIDNEY FUNCTION TESTS; KIDNEY NEOPLASMS; NAPHTHALENES; PARATHYROID NEOPLASMS; PARATHYROIDECTOMY; TREATMENT REFUSAL;

EID: 65549103474     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/S1575-0922(09)70843-5     Document Type: Article

References (13)

1. Farford B., Presutti R.J., and Moraghan T.J. Nonsurgical management of primary hyperparathyroidism. Mayo Clin Proc 82 (2007) 351-355
2. Lambrinoudaki I., Christodoulakos G., and Botsis D. Bisphosphonates. Ann N Y Acad Sci 1092 (2006) 397-402
3. Major P., Lortholary A., Hon J., Abdi E., Mills G., Meussen H.Y., et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19 (2001) 558-567
4. Lyles K.W., Colón-Emeric C.S., Magaziner J.S., Abadri J.D., Pieper C.F., Mautalen C., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357 (2007) 1799-1809
5. Lipton A. The safety of zoledronic acid. Expert Opin Drug Saf 6 (2007) 305-313
6. Dong B.J. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism. Clin Ther 27 (2005) 1725-1751
7. Torres P.U. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease. J Ren Nutr 16 (2006) 253-258
8. Sterrett J.R., Strom J., Stummvoll H.K., Bahner U., Disney A., Soroka S.D., et al. Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 68 (2007) 10-17
9. Silverberg S.J., Rubin M.R., Faiman C., Peacock M., Shoback D.M., Smallridge R.C., et al. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab 92 (2007) 3803-3808
10. Mittendorf E.A., and McHenry C.R. Parathyroid carcinoma. J Surg Oncol 89 (2005) 136-142
11. Silverberg S.J., Bone III H.G., Marriott T.B., Locker F.G., Thys-Jacobs S., Dziem G., et al. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Med 337 (1997) 1506-1510
12. Shoback D.M., Bilezikian J.P., Turner S.A., McCary L.C., Guo M.D., and Peacock M. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 88 (2003) 5644-5649
13. Peacock M., Bilezikian J.P., Klassen P.S., Guo M.D., Turner S.A., and Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 90 (2005) 135-141